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Abstract
The emergence of multidrug resistant bacteria has prioritized the development of new antibiotics. N-substituted
pantothenamides, analogs of the natural compound pantetheine, were reported to target bacterial coenzyme A biosynthesis,
but these compounds have never reached the clinic due to their instability in biological fluids. Plasma-stable pantothenamide
analogs could overcome these issues. We first synthesized a number of bioisosteres of the prototypic pantothenamide
N7-Pan. A compound with an inverted amide bond (CXP18.6-012) was found to provide plasma-stability with minimal loss
of activity compared to the parent compound N7-Pan. Next, we synthesized inverted pantothenamides with a large variety of
side chains. Among these we identified a number of novel stable inverted pantothenamides with selective activity against
Gram-positive bacteria such as staphylococci and streptococci, at low micromolar concentrations. These data provide future
direction for the development of pantothenamides with clinical potential.
Introduction
There is an ongoing need for new drug scaffolds and targets
to combat the increasing development of resistant bacterial
strains. Methicillin-resistant and vancomycin-resistant Sta-
phylococcus aureus (S. aureus) strains (MRSA and VRSA)
have led to serious health problems in both hospital settings
and the community, but resistance to antibiotics is certainly
not limited to these examples. Pantothenate or pantothenic
acid (vitamin B5) is required for coenzyme A (CoA) bio-
synthesis and is an essential and rate limiting nutrient for
survival and/or growth of numerous bacteria, fungi and
protozoa. A range of compounds analogous to pantothenate
or to its cysteamine conjugate pantetheine (see Fig. 1a) have
been reported that possess activity against bacteria, fungi and
malaria parasites (for a review see ref. [1]). In 1970,
N-substituted pantothenamides (in short: pantothenamides),
were first reported to possess antibacterial activity in vitro
(see Fig. 1b for the general pantothenamide structure) [2].
Pantothenamides are pantetheine analogs, of which the pro-
totypic members N-pentylpantothenamide (N5-Pan) and
N-heptylpantothenamide (N7-Pan) were found to be active
against Gram-negative and Gram-positive bacteria [3]. Dur-
ing the last few decades, a number of additional pantothe-
namides with antibacterial activity have been synthesized
[4–8] and their putative modes of action have been studied in
detail [7–11]. Pantothenamides have been shown to serve as
substrates or inhibitors (either competitive or allosteric) of
pantothenate kinase (PanK), the first enzyme in the CoA
biosynthesis pathway [4, 5, 7, 8]. As a consequence, PanK-
catalyzed pantothenate phosphorylation is partially or com-
pletely inhibited. In the case that pantothenamides serve as
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PanK substrates, competing with the natural substrate pan-
tothenic acid, the resulting 4′-phosphopantothenamides may
be further metabolized by the CoA biosynthetic machinery to
yield analogs of CoA, as was shown for Escherichia coli
(E. coli) [9, 10]. Such CoA analogs were found to be
incorporated in acyl carrier protein, thereby inhibiting its
function in bacterial fatty acid biosynthesis, which requires
the 4′-phosphopantetheine moiety of CoA to be active [12].
Whether the mechanisms that ultimately result in anti-
microbial activity in the various target organisms (bacteria,
fungi, protozoa) are the result of inhibition of CoA bio-
synthesis, fatty acid biosynthesis or another CoA-utilizing
process, or a combination of the above, remains to be
resolved for most organisms. The mechanism of action in S.
aureus, however, has recently been investigated in detail
indicating that PanK is the target enzyme [7].
Despite their potential use and selectivity for bacterial,
fungal, and/or protozoan metabolic routes, no pantothena-
mide compound has ever made it to the clinic. It was
recently shown that pantothenamides are not active as
antimicrobials in the presence of serum, and that they were
hydrolyzed by ubiquitous pantetheinases of the vanin
family (see Fig. 1b) [13–16]. To address this, a series of
vanin inhibitors based on a pantothenate scaffold were
synthesized, which proved to inhibit serum vanin activity in
the nanomolar range [17]. Combinations of these novel
vanin inhibitors and prototypic pantothenamides like N5-
Pan and N7-Pan exert antimicrobial activity in vitro, parti-
cularly against Gram-positive bacteria (S. aureus, Staphy-
lococcus epidermidis (S. epidermidis), Streptococcus
pneumonia (S. pneumoniae), and Streptococcus pyogenes
(S. pyogenes)) even in the presence of serum [18]. These
results indicate that pantothenamides, when protected
against degradation by host vanins, are potentially useful
antimicrobial agents [15, 16].
As combinations of compounds are less desirable from a
drug development perspective, chemical modification of
pantothenamides to render them more stable would be
preferable. Taking this approach, modified pantothenamides
were generated that were active antimalarials or anti-
bacterials in the presence of serum [19–23]. As the
hydrolysis-susceptible amide bond was still present in these
modifications or the potency was reduced significantly, we
aimed to generate bioisosteric pantothenamides that would
mimic the chemical space of the amide bond, but would
lack the vanin sensitivity, without losing their potency. Here
we describe such stable bioisosteric compounds as a starting
point for lead optimization.
Materials and methods
Chemistry of inverted pantothenamides
General procedure A
To a solution of carboxylic acid B (0.5 mmol) in MeCN/
H2O (30:1, 4.3 ml) were added HOBt (0.6 mmol), NaHCO3
(0.6 mmol), EDCI (0.6 mmol), and a solution of amine
A (for the synthesis see ref 2, 0.6 mmol) in MeCN/H2O
(0.7 ml). The progress of the reaction was monitored using
LC-MS and upon completion, the reaction was quenched by
the addition of saturated aqueous NH4Cl solution (15 ml)
and the mixture was extracted twice using EtOAc (15 ml).
The combined organic layers were dried over Na2SO4 and
filtered before concentration under reduced pressure. The
residue was purified by flash column chromatography
(DCM/MeOH= 98:2→ 80:20) to afford the product.
CXP18.6-012
According to general procedure A. Yield: 24%, white solid.
1H NMR (400MHz, CDCl3): δ 7.23 (br s, 1H), 6.15 (br s,
1H), 4.01 (s, 1H), 3.84 (br s, 1H), 3.55–3.34 (m, 6H), 3.22
Fig. 1 General structures:
a Chemical structure of
pantetheine. b General structure
of pantothenamide and its
products pantothenic acid and
the corresponding amine after
hydrolysis by vanins. The vanin
sensitive amide bond is marked
as well as the C2-linker between
the amides
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(br s, 1H), 2.20–2.14 (m, 2H), 1.70–1.55 (m, 2H), 1.35–1.20
(m, 8H), 1.04 (s, 3H), 0.96 (s, 3H), 0.88 (t, J= 6.9 Hz,
3H).
CXP18.6-013
According to general procedure A. Yield: 40%, white
solid. 1H NMR (400MHz, CDCl3): δ 7.28 (br s, 1H), 6.26
(br s, 1H), 4.10-3.97 (m, 2H), 3.55–3.30 (m, 7H), 2.21–2.13
(m, 2H) 1.65–1.55 (m, 2H), 1.38–1.22 (m, 4H), 1.03
(s, 3H), 0.95 (s, 3H), 0.88 (t, J= 7.0 Hz, 3H).
CXP18.6-014
According to general procedure A. Yield: 66%, white
solid. 1H NMR (400MHz, CDCl3): δ 7.27 (br s, 1H), 6.23
(br s, 1H), 4.03–3.98 (m, 2H), 3.53–3.33 (m, 7H),
2.20–2.14 (m, 2H), 1.65–1.54 (m, 2H), 1.34–1.20 (m, 12H),
1.03 (s, 3H), 0.95 (s, 3H), 0.88 (t, J= 6.9 Hz, 3H).
CXP18.6-017
According to general procedure A. Yield: 35%, colorless
oil. 1H NMR (400MHz, CD3OD): δ 7.28–7.17 (m, 2H),
7.11–6.98 (m, 2H), 3.88 (s, 1H), 3.46 (d, J= 11.0 Hz, 1H),
3.39 (d, J= 11.0 Hz, 1H), 3.33–3.22 (m, 4H), 2.98–2.92
(m, 2H), 2.51–2.54 (m, 2H), 0.92 (s, 3H), 0.92 (s, 3H).
CXP18.6-069
According to general procedure A. Yield: 43%, colorless oil.
1H NMR (400MHz, CD3OD): δ 7.30–7.23 (m, 1H),
6.93–6.83 (m, 2H), 3.88 (s, 1H), 3.46 (d, J= 11.0 Hz, 1H),
3.39 (d, J= 11.0 Hz, 1H), 3.33–3.22 (m, 4H), 2.92 (app t, J=
7.7 Hz, 2H), 2.48–2.42 (m, 2H), 0.92 (s, 3H), 0.92 (s, 3H).
CXP18.6-047
According to general procedure A. Yield: 25%, colorless
oil. 1H NMR (400MHz, CD3OD): δ 7.18 (dd, J= 5.1, 1.2
Hz, 1H), 6.90 (dd, J= 5.1, 3.4 Hz, 1H), 6.86–6.81 (m, 1H),
3.87 (s, 1H), 3.46 (d, J= 11.0 Hz, 1H), 3.39 (d, J= 11.0
Hz, 1H), 3.35–3.23 (m, 4H), 3.17–3.09 (m, 2H), 2.56–2.49
(m, 2H), 0.92 (s, 3H), 0.92 (s, 3H).
CXP18.6-057
According to general procedure A. Yield: 48%, off-white
solid. 1H NMR (400MHz, CD3OD): δ 7.35 (dd, J= 1.9,
0.8 Hz, 1H), 6.28 (dd, J= 3.2, 1.9 Hz, 1H), 3.89 (s, 1H),
3.46 (d, J= 11.0 Hz, 1H), 3.39 (d, J= 11.0 Hz, 1H),
3.36–3.25 (m, 4H), 2.96–2.86 (m, 2H), 2.55–2.45 (m, 2H),
0.93 (s, 3H), 0.92 (s, 3H).
CXP18.6-064
According to general procedure A. Yield: 92%, colorless
oil. 1H NMR (400MHz, CD3OD): δ 7.10 (app t, J= 7.9 Hz,
1H), 6.92–6.83 (m, 2H), 3.88 (s, 1H), 3.46 (d, J= 11.0 Hz,
1H), 3.39 (d, J= 11.0 Hz, 1H), 3.33–3.22 (m, 4H),
2.94–2.85 (m, 2H), 2.48–2.40 (m, 2H), 2.30 (s, 3H), 0.92
(s, 3H), 0.91 (s, 3H).
CXP14.18-005
According to general procedure A. Yield: 25%, colorless
oil. 1H NMR (400MHz, CDCl3): δ 7.30 (br s, 1H), 6.32 (br
s, 1H), 4.02 (s, 1H), 3.51 (s, 2H), 3.49–3.34 (m, 4H),
2.22–2.15 (m, 2H), 1.62–1.46 (m, 3H), 1.03 (s, 3H), 0.96
(s, 3H), 0.91 (s, 3H), 0.89 (s, 3H).
CXP14.18-012
According to general procedure A. Yield: 88%, white
solid. 1H NMR (400MHz, CDCl3): δ 7.28 (br s, 1H), 6.26
(br s, 1H), 4.01 (s, 1H), 3.51 (s, 2H), 3.50–3.31 (m, 4H),
2.20–2.14 (m, 2H), 1.65–1.55 (m, 2H), 1.37–1.18 (m, 16H),
1.30 (s, 3H), 0.95 (s, 3H), 0.88 (t, J= 6.9 Hz, 3H).
CXP14.26-007
According to general procedure A. Yield: 28%, white waxy
solid. 1H NMR (400MHz, CD3OD): δ 3.98 (dd, J= 8.0,
3.9 Hz, 1H), 3.89 (s, 1H), 3.47 (ABd, J= 10.9 Hz, 1H),
3.40 (ABd, J= 10.9 Hz, 1H), 3.40–3.30 (m, 4H), 1.81–1.70
(m, 1H), 1.63–1.52 (m, 1H), 1.46–1.27 (m, 4H), 1.0–0.85
(m, 9H).
CXP14.18-037
Amine A (1.50 g, 7.88 mmol) was dissolved in acetone
(25 ml) and cooled to 4 °C. 2-Methoxyprop-1-ene (2.26 ml,
23.6 mmol) and TsOH (1.65 g, 8.67 mmol) were added and
after 15 min the cooling bath was removed. The reaction
was stirred for 18 h and then quenched by the addition of
Et3N (1.60 g, 15.7 mmol), followed by 12.5% aqueous
ammonia (15 ml). The mixture was extracted twice with
DCM (15 ml) and the combined organic layers were con-
centrated under reduced pressure. The residue was purified
by flash column chromatography (EtOAc/MeOH/25% aq.
NH4OH= 90:10:1→ 50:50:1) to afford 1.07 g amine C as a
colorless oil. Yield: 30%. 1H NMR (400MHz, CD3OD):
δ 4.15 (s, 1H), 3.75 (ABd, J= 11.7 Hz, 1H), 3.24–3.30
(m, 3H), 2.73 (m, 2H), 1.46 (s, 3H), 1.45 (s, 3H), 1.00
(s, 3H), 0.99 (s, 3H).
To a solution of 2-(propylthio)acetic acid (0.15 g, 0.81
mmol) in a mixture of MeCN (4.4 ml) and H2O (0.24 ml)
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were added HOBt (0.11 g, 0.71mmol), DIPEA (0.14ml,
0.81mmol), EDC (0.14 g, 0.72mmol) and amine C (0.15 g,
0.65mmol). The reaction was stirred at room temperature for
2 h, before the addition of EtOAc (10ml). The mixture was
washed with saturated aqueous NH4Cl (10ml), and saturated
aqueous NaHCO3 (10ml), dried over Na2SO4 and filtered
before concentration under reduced pressure. The residue was
purified by flash column chromatography (EtOAc/MeOH=
95:5→ 90:10) to afford amide D (147mg, 65%).
To a solution of amide D (0.15 g, 0.42 mmol) in MeCN
(2.1 ml) was added an aqueous 0.2 M solution of HCl (2.12
ml, 0.42 mmol). The mixture was stirred at room tempera-
ture for 2 h. The mixture was added dropwise to a mixture
of saturated aqueous NaHCO3 (2 ml) and EtOAc (10 ml).
The layers were separated and the aqueous phase was
saturated with NaCl and then extracted with EtOAc (10 ml).
The combined organic layers were dried over Na2SO4 and
filtered before concentration under reduced pressure to
afford CXP14.18-037 (113 mg, 85%) as a pale yellow
oil. 1H NMR (400MHz, CDCl3): δ 7.30 (br s, 1H), 6.30
(br s, 1H), 4.13 (d, J= 5.0 Hz, 1H), 4.01 (d, J= 5.0 Hz,
1H), 3.55–3.33 (m, 7H), 2.22–2.15 (m, 2H), 1.65–1.53
(m, 2H), 1.39–1.25 (m, 2H), 1.03 (s, 3H), 0.95 (s, 3H), 0.91
(t, J= 7.3 Hz, 3H).
CXP14.18-028
According to the sequence used for CXP14.18-037. Yield
(from C): 55%, colorless oil. 1H NMR (400MHz, CD3OD):
δ 3.89 (s, 1H), 3.47 (d, J= 10.9 Hz, 1H), 3.39 (d, J= 10.9
Hz, 1H), 3.40–3.28 (m, 4H), 2.21–2.15 (m, 2H), 1.65–1.53
(m, 2H), 1.44–1.29 (m, 2H), 0.94–0.91 (m, 9H).
CXP14.18-034
According to the sequence used for CXP14.18-037. Yield
(from C): 37%, pale yellow oil. 1H NMR (400MHz,
CDCl3): δ 7.25 (br s, 1H), 6.32 (br s, 1H), 4.02 (d, J= 5.1
Hz, 1H), 3.97 (d, J= 5.1 Hz, 1H), 3.55–3.27 (m, 7H), 2.53
(t, J= 7.0 Hz, 2H), 2.31 (t, J= 7.4 Hz, 2H), 2.09 (s, 3H),
1.99–1.87 (m, 2H), 1.03 (s, 3H), 0.95 (s, 3H).
CXP14.18-038
According to the sequence used for CXP14.18-037. Yield
(from C): 34%, colorless oil. 1H NMR (400MHz, CDCl3):
δ 7.28 (br s, 1H), 6.44 (br s, 1H), 4.03–3.93 (m, 1H),
3.55–3.33 (m, 7), 2.90–2.70 (m, 2H), 2.55 (q, J= 7.8 Hz,
2H), 2.53–2.38 (m, 2H), 1.26 (t, J= 7.8 Hz, 3H), 1.04
(s, 3H), 0.95 (s, 3H).
Bacterial strains, growth conditions, and MIC assay
The following bacterial strains were used in this study. S.
aureus (ATCC6538, ATCC29213, Xen36, and MRSA
(clinical isolate kindly provided from RIVM)), S. epi-
dermidis (ATCC12228, ATCC14990 and Bactimm 389
(clinical isolate provided from Bactimm)), S. pyogenes
(SS91, SS410 and SS799), Escherichia coli (ATCC25922),
Pseudomonas aeruginosa (ATCC15692), Mycobacterium
avium (ATCC700898), Mycobacterium abscessus
(CIP104536), and Mycobacterium kansasii (ATCC25221).
All strains, except mycobacteria, were grown overnight on
Columbian blood agar plates (Thermo Scientific) at 37 °C.
Slow growing mycobacteria (SGM,M. avium andM. kansasii)
were grown for 5–7 days in Middlebrook 7H9 Broth supple-
mented with 10% oleic acid, albumin, dextrose, and catalase
(OADC) at 37 °C. Rapid growing mycobacteria (RGM, M.
abscessus) were grown for 3 days in Middlebrook 7H9 Broth
at 30 °C. S. pyogenes strains were incubated at 5% CO2, while
all other strains grow in normal atmosphere. Liquid cultures of
S. aureus, S. epidermidis, E. coli, and P.aeruginosa were
grown in Mueller-Hinton Broth (BD Difco) at 37 °C while
shaking and S. pyogenes were grown statically in 5% CO2 at
37 °C in Todd Hewitt Broth (BD Bacto).
To test the MIC of compounds on S. aureus, S. epi-
dermidis, S. pyogenes, E. coli, and P. aeruginosa overnight
cultures were diluted 1:1000 in fresh media and 100 µl was
added to 100 µl of serial diluted compound in 96-well
plates. Plates were incubated at 37 °C (S. pyogenes in 5%
CO2, others in normal atmosphere) for 16 h and MICs were
determined optically. The MIC was defined as the first well
where no bacterial growth was observed. To test the MIC of
compounds on M. avium, M. kansasii, and M. abscessus, a
0.5 McFarland suspension was made of the cultured strains
during log phase growth. This suspension was then diluted
to obtain an inoculum of 1 × 105–1 × 106 CFUml−1 in
Cation Adjusted Mueller-Hinton broth (with 20% OADC
for SGM) and 50 µl was added to 50 µl of serial diluted
compound in 96-well plates. Plates were incubated at 37 °C
for 7 days for SGM and at 30 °C for 3 days for RGM. MICs
were determined optically. The MIC was defined as the first
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well where no bacterial growth was observed. The results
are the median values of at least three independent assays.
Antimicrobial activity of N7-Pan and CXP18.6-012 in
the presence of serum was performed as follows: to mimic
human serum as much as possible, the highest concentration
of serum (10%) was used that did not interfere with the
optical readout. Complement inactivation of human serum
(30 min at 56 °C) was necessary to prevent antimicrobial
activity of the complement system. Because heat inactiva-
tion of serum also led to decreased vanin activity, we
supplemented the serum with fetal bovine serum (FBS) in a
ratio of 4:1. The vanin activity in FBS is extremely high
compared to human serum, leading to a total vanin activity
in the assay that resembles full human serum. Furthermore,
the standard MIC assay was performed as described above.
LC-MS analysis
To examine the stability of analogs in vitro, N5-Pan, its
bioisostere CXP18.6-013, N7-Pan and its bioisostere
CXP18.6-12 were incubated for 16 h at room temperature in
500 µM potassium buffer with and without 10% fetal
bovine serum as a source of pantetheinase activity. Samples
were taken and analyzed by LC-MS using a Shimadzu
LC10ATvp HPLC coupled to a Shimadzu LCMS2010A
mass spectrometer. The elution of the following molecules
were shown: N5-Pan and CXP18.6-013 (271 [M-H2O+H
+]), N7-Pan and CXP18.6-012 (299[M- H2O+H+]), pan-
tothenate (220 [M+H+]) and N2-(aminoethyl)−2,4-dihy-
droxy-3,3-dimethylbutyramide (191 [M+H+]).
Cytotoxicity assay
Primary human keratinocytes obtained from biopsies of
healthy volunteers were cultured following the Rheinwald-
Green system at 37 °C and 5% CO2 [24]. Cells were grown
until they reached confluency. Compounds were added to
these cultures at a concentration of 100 µM and effect on
growth and toxicity was determined microscopically after
24 h. Cytotoxicity was detected using the LDH cytotoxicity
detection kit according to the manufacturer’s protocol
(Roche Applied Science, IN).
Results
Synthesis of N7-pan bioisosteres
We investigated the structure-activity relationship of pan-
tothenamide modifications by varying the N7-Pan molecule on
three different positions, as indicated in Fig. 1b: the C2 linker
between the two amides, the second amide bond and the right
hand part of the molecule (further referred to as side chain).
Table 1 lists the structural modifications in the C2 linker and
amide bond of N7-Pan, and their effects on the minimal
inhibitory concentration (MIC) values. It turned out that only a
C2 linker was allowed. Substitution by an alkene or aromatic
moiety was not allowed. The amide bond was probed by
replacing with different bioisosteres, whilst keeping the C2
linker intact. Replacement by a keto, ester or a sulfonamide
moiety was not allowed. Replacement by 5-membered ring
amide bioisosteres was in general not successful, although in
some cases minor activity was demonstrated. The only effec-
tive modification which yielded activities comparable to the
parent compound was substitution of the amide bond by an
inverted amide as shown in compound CXP18.6-012. Like
N7-Pan, none of its bioisosteres showed activity against the
Gram-negative bacteria that were tested (E. coli and P. aeru-
ginosa) or the Mycobacterium species that were tested
(M. avium, M. abscessus and M. kansasii). Some bioisosteres
showed weak activities against S. epidermidis and S. pyogenes
(MIC between 8 and 32 μgml−1). Only bioisostere CXP18.6-
012 showed activity against S. aureus, with a MIC value of 2
μgml−1, which is close to the potency of the parent compound
N7-Pan. However, this modification decreased the potency
towards S. epidermidis from 0.5 to 8 μgml−1, whereas the
sensitivity towards S. pyogenes was decreased from 2 to 32 μg
ml−1. In addition, we synthesized the inverted amide bioisos-
tere of another prototypical pantothenamide, N5-Pan, desig-
nated as CXP18.6-013 (see also Supplemental Table 1).
This compound showed good activity towards S.pyogenes
(2 μgml−1) and weak activity towards S. epidermidis and S.
aureus (resp. 16 and 32 μgml−1). The experimental details on
the synthesis of the compounds of Table 1 are given in online
Supplemental File S1, with the exception of CXP18.6-012
which can be found in the Materials and Methods section, and
N7-Pan, which has been described before [2].
Stability of inverted pantothenamides
We incubated the prototypical pantothenamides N5-Pan and
N7-Pan as well as their inverted amide bioisosteres
CXP18.6-012 and CXP18.6-013 in the presence and
absence of fetal bovine serum, and analyzed the stability
towards vanin-mediated hydrolysis, using LC-MS analysis.
In Fig. 2a, c total degradation of N5-Pan and N7-Pan by
serum is shown as the disappearance of the red peak of the
parent compound, whereas the hydrolysis product pan-
tothenate emerges (blue peak). Figures 2b, d show that the
inverted pantothenamides CXP18.6-013 and CXP18.6-012
remain stable after overnight incubation in a serum-
containing buffer.
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Table 1 Bioisosteres of prototypic pantothenamide N7-Pan
MICs were denoted as µg ml−1
MICs up to 32 µg ml−1 are represented in bold
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Activity of inverted pantothenamides under
physiological conditions
We then investigated whether inverted pantothenamides
would retain their ability to kill bacteria, even in the
presence of serum. To test this, we performed MIC assays
in Mueller-Hinton medium to which 10% serum was
added. We tested both human serum and fetal bovine
serum (FBS). Human serum was first decomplemented at
56 °C, which also partly destroys its vanin activity. FBS,
which has an extremely high vanin activity, was used
without heat inactivation, which allowed testing of the
compounds in the presence of a vanin activity which
equals that of 100% human serum. Table 2 shows that
addition of serum abolished the antibiotic properties of
N7-Pan, whereas CXP18.6-012 remained active.
Structural modification of the side chain of inverted
N7-Pan
Having established that the inverted N7-Pan was active and
stable, and knowing that variation of the C2 linker was not
allowed, we aimed to improve its potency or alter the spe-
cificity by modification of the side chain, using the C2
linker a backbone and keeping the second amide bond
inverted. Supplemental Table 1 lists all 72 side chain
modifications and their activity against S. aureus, S. epi-
dermidis, S. pyogenes, E.coli, P. aeruginosa, M. avium, M.
Fig. 2 Stability of inverted pantothenamides in serum. The stability of
compounds was measured using LC-MS analysis after overnight
incubation in buffer with or without 10% fetal bovine serum. Fetal
bovine serum contains high levels of pantetheinase activity. a N5-Pan
(red line) was stable in buffer, but completely degraded when serum
was added. The blue peak represents pantothenate, the product after
pantetheinase-derived degradation. b CXP18.6-013 (red line), the
inverted amide of N5-Pan remain stable in serum-containing buffer,
indicating it is protected against degradation by vanins. The
hypothetical product upon degradation by pantetheinase activity (blue
peak) was not detected. c N7-Pan (red line) was also sensitive for
enzymatic degradation as described in a. d CXP18.6-012 (red line),
the inverted amide from N7-Pan remained stable as described for
CXP18.6-013 (b). Note that the small blue peak in (b) and (d) just
before 2 min of retention is from another molecule of the same mass,
probably an ingredient of the buffer. Total ion current was shown in
gray at 1x intensity, while the other lines were shown at a 10x intensity
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abscessus, and M. kansasii. Both aliphatic and aromatic
substitutions provided active compounds. With aliphatic
side chains the optimum length was C7 and C9. In case of
shorter chain length (C5, C5 with a heteroatom), activity
was mainly observed against S. pyogenes (e.g., CXP18.6-
013, CXP14.18-028, CXP14.18-037, and CXP14.18-034).
It turned out that the C7 aliphatic chain could be replaced by
ethylaromatics. In case of a phenyl being present in the side
chain, a comparable activity profile was found (see
CXP18.6-064, CXP18.6-017, and CXP18.6-069). In case of
aromatic heterocycles, activity against S. pyogenes became
dominant (CXP18.6-047 and CXP18.6-057). None of the
tested inverted pantothenamides was able to inhibit growth
of Gram-negative bacteria or Mycobacterium species at
relevant concentrations (≤32 μg ml−1). The compounds that
showed significant activity towards one of the Gram-
positive bacteria were tested against multiple strains of S.
aureus, S. epidermidis, and S. pyogenes (see Table 3).
Overall, the differences between strains were very small.
The most potent inverted pantothenamides against S. aureus
tested here are CXP18.6-17 (1–2 μg ml−1), CXP18.6-012
(2–8 μg ml−1), CXP18.6-014 (2–8 μg ml−1), and CXP18.6-
069 (2–8 μg ml−1). Towards S. epidermidis the most potent
inverted pantothenamides were CXP18.6-064 (1 μg ml−1),
CXP18.6-014 (2 μg ml−1), CXP18.6-69 (1–2 μg ml−1), and
CXP18.6-17 (2–4 μg ml−1). Strains of S.pyogenes were
most sensitive to CXP14.18-028 (2 μg ml−1), CXP14.18-
037 (2–4 μg ml−1), and CXP14.18-005 (2–8 μg ml−1).
In vitro toxicology
Finally, we used cultured primary human keratinocytes to
obtain limited in vitro toxicology data on inverted pan-
tothenamides. Using LDH release as a measure of viability,
we did not detect cytotoxicity of any of the compounds that
showed antimicrobial activity up to concentrations of 100
μM (~30 μg ml−1).
Discussion
In the present study we describe a new class of stable
pantothenamide bioisosteres that display antibiotic Ta
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Table 2 Effect of serum on MIC of N7-Pan and CXP18.6–012 against
S. aureus ATCC6538
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activity against staphylococci and streptococci. These
compounds target a biochemical pathway that is distinct
from currently marketed drugs, and their activity appears
to be primarily against clinically relevant Gram-positive
species. As there is a strong medical need for improved
small-spectrum antibiotics, stable pantothenamides with
improved potency may be moved forward as promising
compounds for clinical use.
Previous studies have demonstrated that pantothenamide
antibiotics based on the pantothenate/pantetheine scaffold
are labile in biological fluids due to hydrolysis of the amide
bond by serum vanins [13–16]. Our data reveal that inver-
sion of the amide bond afforded a considerable increase of
stability whilst largely preserving the biological activity
[25]. A recent paper by Barnard et al. [20] reported that the
inversion of the amide bond had a dramatic effect on anti-
biotic activity towards the S. aureus RN2440 strain. This is
in contrast to our findings. We have tested multiple strains
and species, and found similar MICs among strains. The
basis for the discrepancy between these studies is presently
unclear, but is currently actively being pursued in colla-
boration with Strauss and co-workers. Other structural
modifications, reported for antimalarial pantothenamides,
that increased the stability include introduction of a methyl
group in the C2 linker [19] and variation of the linker length
[8]. We further explored structural modifications at the side
chain, which did not lead to improved potency compared to
the parent compound. Remarkably, the taxon-specificity
was clearly dependent on the structural modifications in the
molecule. These were found to affect both the specificity at
the genus and the species level for Gram-positive organisms
studied here. We do not think that the pantothenamides as a
class are selective for Gram-positive organisms. In the ori-
ginal paper by Clifton et al[2]. where N5-Pan and N7-Pan
were first described, there was significant activity of N5-Pan
against the Gram-negative organism E. coli. Here we have
developed compounds based on N7-Pan, which appear to be
more potent towards Gram-positive organisms. It has to be
noted that we only tested a number of clinically relevant
genera of Gram-positive and Gram-negative bacteria. A
more extensive screen of bacterial species is required to
establish the sensitivity of other Gram-negative organisms.
The observed lack of sensitivity of E. coli might be
explained by the fact that N7-Pan (and possibly also its
derivatives) is a substrate for TolC-dependent efflux pumps,
as reported by Zhang et al. [10].
Our present study suggests that pantothenamides may be
further optimized to yield small-spectrum antibiotics that
could target a pathogen without affecting the complete
human microbiome. This would be a major advance to
avoid the consequences of broad spectrum antibiotics such
gut microbiota dysbiosis, thereby reducing antibiotic-
associated complications such as diarrhea, Clostridium dif-
ficile infections or candidiasis. An example that such spe-
cificity is feasible is the development of Debio 1450 (now
known as afabicin), an antibiotic candidate with a novel
mechanism of action, currently in phase II clinical devel-
opment for intravenous and oral treatment of staphylococcal
infections [26]. It specifically targets Staphylococcus by
inhibition of FabI, an enzyme essential for fatty acid
synthesis in this genus. Debio 1450 shows a high potency
against staphylococci, particularly MRSA, without cross-
resistance to other antibiotics, including other agents active
against staphylococci. Interestingly, this indicates that bac-
terial fatty acid synthesis is a valid antibiotic target, at least
for S. aureus, which has been questioned previously [27].
As CoA is also required for fatty acid synthesis, pantothe-
namides may also act on bacterial fatty acid synthesis.
Addition of serum, which is a source of host fatty acids, to
our MIC assays did not significantly inhibit the antibiotics
effects. This indicates that exogenous available free fatty
acids do not interfere with the mechanism of action.
The mechanism of action of the prototypic pantothena-
mides has been investigated previously and appears largely
dependent on the PanK type of the organism. For E.coli,
which has a PanKI type enzyme, the presumed mechanism
of action of the pantothenamide N5-pan has been investi-
gated in detail. The formation of coenzyme A anti-
metabolites [9] that interferes with fatty acid synthetic
enzymes [11] and endogenous pantothenate biosynthesis
[28] are two affected pathways that are interrupted. It was
also reported that N5-Pan could inhibit the growth of S.
pneumoniae and that this effect was probably due to fatty
acid synthesis inhibition as it could be outcompeted with
oleate [10]. The molecular mechanism by which pantothe-
namides inhibit growth of other Gram-positive bacteria is
currently unknown, with an exception for S. aureus. In
contrast to other gram-positive bacteria, S. aureus has a
PanKII type enzyme that accepts pantothenamides as a
substrate [8]. The co-crystal structures of SaPanKII and N7-
pan revealed that pantothenamides are phosphorylated but
remain trapped in the active site [7]. Given the differential
effects of many of our compounds towards S. aureus and S.
pyogenes, it is likely that the modes of action are distinct.
Clearly, additional efforts are required to identify
improved inhibitors that may progress to the clinic. So far
we have relied on ligand-based design, but preferably we
would direct future campaigns to structure-based design.
We are currently investigating the mechanism of action of
the pantothenamide bioisosteres.
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